|
|
Article: Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting.
- Article from:
- PR Newswire
- Article date:
- October 31, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Data Shows Faster Resolution of Diarrhea and Improved Outcome in Patients Requiring Concomitant Antibiotics
SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia, PA.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
Mark A. Miller, M.D., head of the Division of Infectious Diseases, Chair of the Infection Prevention and Control Unit at the Jewish General Hospital in Montreal, Quebec, Canada, presented results showing that ...